| Dr Hristo Vassilev Stoytchev, MD | |
|
175 High St, Newton, NJ 07860-1004 | |
| (973) 383-2121 | |
| (973) 898-3905 |
| Full Name | Dr Hristo Vassilev Stoytchev |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 19 Years |
| Location | 175 High St, Newton, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023277290 | NPI | - | NPPES |
| 1023277290 | Medicaid | NV |
| Facility Name | Location | Facility Type |
|---|---|---|
| Karen Ann Quinlan Hospice | Newton, NJ | Hospice |
| Newton Medical Center | Newton, NJ | Hospital |
| Morristown Medical Center | Morristown, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Practice Associates Medical Group | 5890703177 | 1116 |
News Archive
Leading cancer researchers from Baltimore, Miami and New Jersey have organized the first Joint American-Israeli Conference on Cancer. The meeting, scheduled for March 16 through 18 in Jerusalem, seeks to foster collaboration among physicians and scientists in the two countries.
Patient-reported fatigue severity is an independent prognostic marker for survival in patients with newly diagnosed intermediate-2- or high-risk myelodysplastic syndromes, according to research published in The Lancet Oncology.
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated a Phase 2 clinical trial evaluating SCH 900105 (also referred to as AV-299) for the treatment of non-small cell lung cancer. The initiation of this trial triggers an $8.5 million milestone payment by Merck to AVEO resulting from a 2007 agreement between AVEO and Schering-Plough (now Merck).
› Verified 9 days ago
| Entity Name | Practice Associates Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427016385 PECOS PAC ID: 5890703177 Enrollment ID: O20060330000690 |
News Archive
Leading cancer researchers from Baltimore, Miami and New Jersey have organized the first Joint American-Israeli Conference on Cancer. The meeting, scheduled for March 16 through 18 in Jerusalem, seeks to foster collaboration among physicians and scientists in the two countries.
Patient-reported fatigue severity is an independent prognostic marker for survival in patients with newly diagnosed intermediate-2- or high-risk myelodysplastic syndromes, according to research published in The Lancet Oncology.
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated a Phase 2 clinical trial evaluating SCH 900105 (also referred to as AV-299) for the treatment of non-small cell lung cancer. The initiation of this trial triggers an $8.5 million milestone payment by Merck to AVEO resulting from a 2007 agreement between AVEO and Schering-Plough (now Merck).
› Verified 9 days ago
| Entity Name | New Jersey Post Acute Medical Services 1 Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578092391 PECOS PAC ID: 7214200351 Enrollment ID: O20170912000743 |
News Archive
Leading cancer researchers from Baltimore, Miami and New Jersey have organized the first Joint American-Israeli Conference on Cancer. The meeting, scheduled for March 16 through 18 in Jerusalem, seeks to foster collaboration among physicians and scientists in the two countries.
Patient-reported fatigue severity is an independent prognostic marker for survival in patients with newly diagnosed intermediate-2- or high-risk myelodysplastic syndromes, according to research published in The Lancet Oncology.
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated a Phase 2 clinical trial evaluating SCH 900105 (also referred to as AV-299) for the treatment of non-small cell lung cancer. The initiation of this trial triggers an $8.5 million milestone payment by Merck to AVEO resulting from a 2007 agreement between AVEO and Schering-Plough (now Merck).
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Hristo Vassilev Stoytchev, MD Po Box 416457, Boston, MA 02241-6457 Ph: (844) 362-1735 | Dr Hristo Vassilev Stoytchev, MD 175 High St, Newton, NJ 07860-1004 Ph: (973) 383-2121 |
News Archive
Leading cancer researchers from Baltimore, Miami and New Jersey have organized the first Joint American-Israeli Conference on Cancer. The meeting, scheduled for March 16 through 18 in Jerusalem, seeks to foster collaboration among physicians and scientists in the two countries.
Patient-reported fatigue severity is an independent prognostic marker for survival in patients with newly diagnosed intermediate-2- or high-risk myelodysplastic syndromes, according to research published in The Lancet Oncology.
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated a Phase 2 clinical trial evaluating SCH 900105 (also referred to as AV-299) for the treatment of non-small cell lung cancer. The initiation of this trial triggers an $8.5 million milestone payment by Merck to AVEO resulting from a 2007 agreement between AVEO and Schering-Plough (now Merck).
› Verified 9 days ago
Aradhana Aggarwal, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 175 High St, Newton, NJ 07860 Phone: 973-383-2121 | |
Vandankumar Patel, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 175 High St, Newton, NJ 07860 Phone: 973-383-2121 Fax: 973-383-8973 | |
Dr. Daya Nadarajah, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 222 High St, Suite 102, Newton, NJ 07860 Phone: 973-579-5090 Fax: 973-579-7409 | |
Dr. Samir Dilip Shah, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 123 Newton Sparta Rd, Newton, NJ 07860 Phone: 973-579-6300 Fax: 973-579-1524 | |
Dr. Nick Paul Debitetto, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 123 Newton Sparta Rd, Newton, NJ 07860 Phone: 973-579-6300 Fax: 973-579-1524 | |
Dr. Gerald Cioce, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 222 High St, Suite 205, Newton, NJ 07860 Phone: 973-579-2100 Fax: 973-579-6638 |